Want to see JP:8283 full AI Analyst Report?
Top Page
Paltac
(8283)
Select Model
Select Model
Rating:71Outperform
Price Target:
¥7,337.00
▲(51.06% Upside)
Action:Reiterated
Date:05/12/26
The score is driven mainly by strong financial resilience from an exceptionally conservative balance sheet and steady revenue growth, tempered by structurally thin margins and somewhat inconsistent cash-flow momentum. Technical indicators are mildly weak with price below key moving averages and negative MACD, while valuation appears reasonable supported by a ~2.6% dividend yield.
Positive Factors
Conservative balance sheet
Extremely low leverage and consistent equity expansion give Paltac strong financial flexibility and low solvency risk. This durable balance-sheet strength supports investment, dividend stability and resilience in downturns, and preserves access to credit over multiple quarters.
Negative Factors
Thin margins
Structurally thin gross and net margins leave little buffer to absorb rising input, freight or labor costs. Limited margin headroom reduces earnings sensitivity to revenue growth and constrains the ability to finance margin-enhancing initiatives without higher volumes or pricing power.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low leverage and consistent equity expansion give Paltac strong financial flexibility and low solvency risk. This durable balance-sheet strength supports investment, dividend stability and resilience in downturns, and preserves access to credit over multiple quarters.
Read all positive factors
Paltac (8283) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥406.93B
Dividend Yield2.3%
Average Volume (3M)64.93K
Price to Earnings (P/E)18.5
Beta (1Y)0.50
Revenue Growth4.19%
EPS Growth-2.02%
CountryJP
Employees1,478
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)358.96
Shares Outstanding62,000,000
10 Day Avg. Volume61,240
30 Day Avg. Volume64,930
Financial Highlights & Ratios
PEG Ratio-6.56
Price to Book (P/B)0.98
Price to Sales (P/S)0.24
P/FCF Ratio12.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)365.9
Revenue Forecast (FY)¥1.27T
Paltac Business Overview & Revenue Model
Company Description
Established in 1898 and headquartered in Osaka, Japan, Paltac Corporation serves as a prominent wholesaler of beauty products, household goods, and non-prescription medicines throughout Japan. The firm operates as a subsidiary of MediPal Holdings ...
How the Company Makes Money
Paltac makes money primarily by wholesaling consumer packaged goods to retailers. Its core revenue stream is net sales generated from purchasing products from manufacturers and selling them to retail customers (e.g., supermarkets, drugstores, home...
Paltac Financial Statement Overview
Summary
Income Statement
71
Positive
Balance Sheet
92
Very Positive
Cash Flow
66
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.24T | 1.19T | 1.15T | 1.10T | 1.05T |
| Gross Profit | 88.26B | 84.92B | 82.11B | 78.03B | 77.36B |
| EBITDA | 38.13B | 39.16B | 35.92B | 33.56B | 33.85B |
| Net Income | 22.03B | 22.86B | 20.64B | 19.25B | 19.64B |
Balance Sheet | |||||
| Total Assets | 532.17B | 511.93B | 500.31B | 480.99B | 452.96B |
| Cash, Cash Equivalents and Short-Term Investments | 83.28B | 69.92B | 60.99B | 45.99B | 40.67B |
| Total Debt | 475.00M | 349.00M | 252.00M | 244.00M | 315.00M |
| Total Liabilities | 230.43B | 224.26B | 222.34B | 221.28B | 209.21B |
| Stockholders Equity | 301.74B | 287.67B | 277.96B | 259.70B | 243.74B |
Cash Flow | |||||
| Free Cash Flow | 22.85B | 19.27B | 21.12B | 11.04B | 12.82B |
| Operating Cash Flow | 24.93B | 20.68B | 26.79B | 16.59B | 21.95B |
| Investing Cash Flow | -402.00M | -428.00M | -6.27B | -6.09B | -10.17B |
| Financing Cash Flow | -11.16B | -11.32B | -5.52B | -5.18B | -8.73B |
Paltac Technical Analysis
Positive
4857.00
Price Trends
6085.38
Positive
5436.09
Positive
5035.48
Positive
Market Momentum
117.21
Positive
83.45
Negative
53.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8283, the sentiment is Positive. The current price of 4857 is below the 20-day moving average (MA) of 6637.70, below the 50-day MA of 6085.38, and below the 200-day MA of 5035.48, indicating a bullish trend. The MACD of 117.21 indicates Positive momentum. The RSI at 83.45 is Negative, neither overbought nor oversold. The STOCH value of 53.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8283.
Paltac Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥540.93B | 15.37 | 12.66% | 1.53% | 11.37% | 11.35% | |
71 Outperform | ¥406.93B | 18.52 | 7.40% | 2.30% | 4.19% | -2.02% | |
70 Outperform | ¥2.88T | 22.85 | 11.50% | 2.41% | 3.60% | 13.80% | |
69 Neutral | ¥292.95B | 28.60 | 2.72% | 2.61% | 1.63% | 74.87% | |
65 Neutral | ¥402.48B | 131.47 | 5.37% | 1.95% | 3.14% | -71.37% | |
64 Neutral | ¥463.82B | 17.03 | 9.09% | 1.73% | 3.10% | 27.99% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
* Consumer Defensive Sector Average
JP:8283
Paltac
6,641.00
2,721.61
69.44%
JP:4452
Kao
3,267.00
149.38
4.79%
JP:4967
Kobayashi Pharmaceutical Co
5,505.00
287.04
5.50%
JP:4922
Kose
5,279.00
-465.17
-8.10%
JP:4912
Lion
1,729.50
277.65
19.12%
JP:4527
Rohto Pharmaceutical Co
2,391.50
363.51
17.92%
Paltac Corporate Events
Paltac Backs Medipal Tender Offer as It Emphasizes Governance and Independence
Jun 19, 2026
Paltac has clarified its position within the Medipal Holdings group, noting that Medipal holds 52.44% of its voting rights and that Paltac independently manages the group’s cosmetics, daily necessities and OTC pharmaceutical wholesale busine...
Paltac Reshapes Top Management Roles in Logistics and Administration
Jun 19, 2026
Paltac Corporation announced changes to its leadership structure following a Board of Directors meeting held on June 19, 2026, adjusting key management roles in administration and logistics. Director and Senior Managing Executive Officer Masahiro ...
Paltac Sets Record Date for Potential EGM Linked to Medipal Tender Offer
Jun 19, 2026
PALTAC Corporation has set July 15, 2026, as the record date for shareholders eligible to vote at a potential extraordinary general meeting planned for around late August 2026, adjusting the timing from an earlier indication of September. Sharehol...
Paltac Lifts Sales but Cuts Outlook as Medipal Buyout Paves Way for Delisting
May 25, 2026
Paltac reported non-consolidated net sales of ¥1.24 trillion for the year ended March 31, 2026, up 4.2% year on year, while operating profit fell 5.6% to ¥26.4 billion and ordinary profit declined 5.9% to ¥29.8 billion, leading to a...
Paltac Backs Medipal Tender Offer Aimed at Full Ownership and Delisting
May 11, 2026
Paltac Corp., a major Japanese wholesaler of pharmaceuticals, cosmetics, and daily necessities, is currently a consolidated subsidiary of Medipal Holdings, which owns just over half of its outstanding shares. The two companies maintain close capit...
Paltac Scraps FY 2026–27 Dividends Ahead of Medipal Takeover Bid
May 11, 2026
Paltac Corporation’s board has decided not to pay interim or year-end dividends for the fiscal year ending March 31, 2027, covering record dates of September 30, 2026 and March 31, 2027. This marks a sharp shift from the prior year, when the...
Paltac Halts Share Buyback as It Backs Parent Medipal’s Tender Offer
May 11, 2026
Paltac Corporation has resolved to discontinue its previously approved share buyback program, which had authorized repurchases of up to 1.5 million shares or ¥5.0 billion between August 2025 and May 2026. The company had already acquired 1,04...
Paltac lifts sales and dividends as it prepares for delisting under Medipal
May 11, 2026
Paltac reported a 4.2% rise in net sales to ¥1.24 trillion for the fiscal year ended March 31, 2026, while operating profit fell 5.6% to ¥26.4 billion and profit declined 3.6% to ¥22.0 billion, reflecting margin pressure despite top...
Paltac Nears Completion of ¥5 Billion Share Buyback Program
May 8, 2026
Paltac has continued its previously approved share buyback program, acquiring 131,500 common shares on the Tokyo Stock Exchange between April 1 and April 30, 2026, at a total cost of approximately ¥621.7 million. This move is part of a broade...
Paltac to Build Next-Generation AI-Driven Distribution Hub in Osaka
Apr 27, 2026
Paltac will construct a new next-generation distribution center, provisionally named RDC Kaizuka, in Kaizuka City, Osaka Prefecture on company-owned land, with operations slated to start in March 2030. The ¥34.9 billion facility is designed t...
PALTAC Nears Completion of ¥5 Billion Share Buyback Program
Apr 3, 2026
PALTAC CORPORATION has reported the latest status of its ongoing share buyback program, authorized by its Board of Directors in August 2025 under the Companies Act and the company’s Articles of Incorporation. The company acquired 98,900 shar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.